Literature DB >> 6328324

Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells.

M Seiki, R Eddy, T B Shows, M Yoshida.   

Abstract

Human T-cell leukaemia virus (HTLV), previously also reported as ATLV, is a recently identified retrovirus which is closely associated with adult T-cell leukaemia (ATL) endemic in southwestern Japan and the Caribbean. Determination of the total nucleotide sequence of the HTLV genome has revealed no typical onc gene acquired from the cellular sequence. Screening of the HTLV provirus genome in tumour cells has shown that in all cases of ATL examined, the primary tumour cells contained the provirus genome and were monoclonal with respect to the integration site of the provirus. These findings suggest that ATL leukaemogenesis may be due to insertional mutagenesis in which the provirus genome is integrated into a specific locus on the chromosomal DNA and then activates an adjacent cellular onc gene, a mechanism already demonstrated in avian lymphoma and erythroblastosis induced by avian leukosis viruses. A common site of HTLV provirus integration in leukaemic cells among some ATL patients was reported by Hahn et al. but subsequently retracted. However, this retraction does not imply the random integration of the proviruses. Independently, we have been testing this insertional mutagenesis model in ATL and report here that the provirus did not have a common locus of integration in 35 ATL patients and did not integrate on the same chromosome in 2 ATL patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328324     DOI: 10.1038/309640a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  72 in total

1.  Vertical transmission of human T-cell leukemia virus type I (HTLV-I): detection of proviral DNA in HTLV-I carrier gravida.

Authors:  F Saji; Y Tokugawa; S Kamiura; Y Samejima; K Ohashi; C Azuma; O Tanizawa
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

2.  Studies of heterologous promoter trans-activation by the HTLV-II tax protein.

Authors:  J L Williams; A J Cann; T Leff; P Sassone-Corsi; I S Chen
Journal:  Nucleic Acids Res       Date:  1989-07-25       Impact factor: 16.971

3.  Chronic adult T-cell leukaemia/lymphoma presenting with cutaneous manifestations.

Authors:  W G Phillips; J A Langtry; C Formstone; A M Taylor; J R Marsden
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

4.  Human T-cell leukemia virus open reading frame II encodes a posttranscriptional repressor that is recruited at the level of transcription.

Authors:  Ihab Younis; Kathleen Boris-Lawrie; Patrick L Green
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Temporal regulation of viral and cellular gene expression during human T-lymphotropic virus type I-mediated lymphocyte immortalization.

Authors:  J T Kimata; L Ratner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 6.  Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia.

Authors:  M R Smith; W C Greene
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 7.  Leukemogenesis of adult T-cell leukemia.

Authors:  Jun-ichirou Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Authors:  Ryuta Sakuma; Toshie Sakuma; Seiga Ohmine; Robert H Silverman; Yasuhiro Ikeda
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

9.  The prevalence of proviral bovine leukemia virus in peripheral blood mononuclear cells at two subclinical stages of infection.

Authors:  M L Mirsky; C A Olmstead; Y Da; H A Lewin
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Chromosomal localization of HTLV-1 viral integration sites using in situ hybridization: detection of a novel IL2R fragment.

Authors:  M J Macera; P Szabo; R S Verma
Journal:  Mol Gen Genet       Date:  1992-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.